There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Official Report
Meeting date:
17 June 2025
Meeting of the Parliament 17 June 2025 [Draft]
We need a full and immediate ceasefire, we need all hostages to be released safely and we need humanitarian aid—food, water, fuel and medicine—to be allowed in without delay, without conditions and without political gains.
Official Report
Meeting date:
5 June 2024
Meeting of the Parliament 05 June 2024
Also—Liam McArthur missed this in an otherwise interesting contribution—2021 figures show that around a quarter of the UK’s oil and gas goes towards manufacturing everyday products. That is medicines, cosmetics and asphalt; it is materials for wind turbines and solar panels.
Last updated:
13 August 2024
JSP20222023
Access to Cannabis-based Products for Medicinal Use: The Parliament debated S6M-03233 in the name of Collette Stevenson—That the Parliament welcomes the Home Office’s rescheduling of certain cannabis-based products for medicinal use (CBPMs) in 2018; notes the reported improvement in some children with treatment resistant epilepsy who take CBPMs, such as Cole Thomson, from East Kilbride, who it understands receives Bedrolite on private prescription; acknowledges the reported financial pressure that these prescriptions can place on families; further acknowledges the reported hesitancy of NHS consultants to prescribe unlicensed CBPMs due to the lack of robust evidence; notes the view that the rescheduling does not go far enough in assisting some patients, and the calls for a change in rules to allow GPs, who consider it appropriate, to prescribe unlicensed CBPMs where a non- NHS consultant has initiated that course of treatment; understands that the British Paediatric Neurology Association published its updated Guidance on the use of 30 Journal of the Scottish Parliament, Session 6, 13 May 2022 – 12 May 2023 cannabis-based products for medicinal use in children and young people with epilepsy in October 2021, which, it considers, outlines concerns around the lack of randomised control trials demonstrating a product’s safety, quality and efficacy; acknowledges the Scottish Government’s reported commitment to collaborate with NHS England and the National Institute for Health Research to support research trials into medicinal cannabis in order to give NHS consultants the assurances that they need to consider prescribing CBPMs on the NHS; understands that, once a medicinal product has undergone clinical trials, it could be considered by the Medicines and Healthcare products Regulatory Agency for licensing and that this could lead to further consideration by organisations such as the National Institute for Health and Care Excellence, the Scottish Medicines Consortium and NHS Scotland; notes the calls for industry to run observational and clinical trials; believes that an increased evidence base offers the best opportunities for expansion of the range of CBPMs available from the NHS; welcomes the reported plans by Target Healthcare, which operates in East Kilbride, to produce CBPMs in Scotland, and notes the calls on the Scottish and UK governments to work together to find solutions on these issues.
Questions and Answers
Date answered:
23 September 2015
S4W-27510
Most patients requiring hospital care for allergies are likely to be recorded under specialties such as dermatology and respiratory medicine. However, a small number of patients in the Greater Glasgow and Clyde area have been recorded under the specialty of allergy; this is likely to reflect patients who have been seen in a dedicated allergy clinic.
Questions and Answers
Date answered:
14 May 2015
S4W-25436
To ask the Scottish Government what its position is on the Cochrane Library review, Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration, which suggests that bevacizumab is an effective and less expensive alternative to ranibizumabin in the treatment of wet macular degeneration and, in light of this, whether it has asked the Scottish Medicines Consortium to consider authorising its use.
Questions and Answers
Date answered:
19 February 2015
S4W-24331
All UK University undergraduate programmes in medicine include training in the diagnosis and management of mental disorder (including personality disorder) and illness.
Questions and Answers
Date answered:
11 June 2014
S4W-21363
Patient and Clinician Engagement now forms part of the Scottish Medicines Consortium (SMC) evaluation process.
Questions and Answers
Date answered:
6 March 2014
S4W-19923
The new peer approved clinical system (PACS) is due to be rolled out in May 2014 and the Scottish Government will publish details of PACS following implementation of a new approach by the Scottish Medicines Consortium. The Scottish Government has listened to the views of patients and patient interest groups regarding a replacement approach to the current i...
Questions and Answers
Date answered:
14 November 2013
S4W-18054
There are a number of licenced sea lice medicines available to the industry: the usage of teflobenzuron was relatively low between 2007 and 2010.
Questions and Answers
Date answered:
25 June 2013
S4W-15666
The Scottish Government has noted the Swedish report and remains in contact with the Medicines and Healthcare products Regulatory Agency.
